Abstract
BackgroundConsidering the highest adverse events risk (predominantly infectious disease and osteoporosis) of glucocorticoids (GCs), EULAR recommended a short-term use of GCs with rapid tapering as soon as clinically feasible in...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have